The improved anti-EGFR-iRGD has significant advantages in solid tumor therapy, especially for the treatment of gastric cancer with various drugs, including DOX, bevacizumab, and PTX, and this effect may be related to the delay of macrophage-mediated drug clearance, which facilitated persistent circulation and enhanced drug delivery into tumors more efficiently [67]. Here, EGFR is linked to gastric cancer.